Biotech investors in Shanghai, China
Updated 16 Nov 2026
Venture funds
6 funds, by portfolio companies funded in the last 12 months| # | Fund | Sectors | Stages | Leads | Funded, 12 months |
|---|---|---|---|---|---|
| 1 | Qiming Venture Partners Qiming Venture Partners invests in technology, consumer and healthcare companies at early and growth stages, with recent investments including Houmo.AI and AusperBio. Shanghai, China |
Health care, Artificial intelligence | Seed, Early stage venture, Late stage venture | 50% | 11 |
| 2 | Med-Fine Capital Med-Fine Capital focuses on healthcare and bio-science, with recent investments including Artivila Therapeutics and Phrontline Biopharma. Shanghai, China |
Health care, Biotech | Early stage venture | 30% | 3 |
| 3 | BioTrack Capital BioTrack Capital invests in life sciences, healthcare technology and biotechnology, with recent companies including Yuce Biotechnology and Rigen Biotech. Shanghai, China |
Health care, Biotech | Seed, Early stage venture, Late stage venture | 33% | 2 |
| 4 | Boyuan Capital Boyuan Capital operates as an investment platform, with recent companies Yuce Biotechnology and Rigen Biotech. Shanghai, China |
Health care, Biotech | Late stage venture | 38% | 2 |
| 5 | Linear Capital Linear Capital invests in data application projects, with recent companies SynMetaBio, Dishi Medical and ReaVis. Shanghai, China |
Artificial intelligence, Hardware | Seed, Early stage venture, Late stage venture | 31% | 2 |
| 6 | 5Y Capital 5Y Capital makes early-stage venture investments, with recent investments in Etern and CellCentric. Xuhui, China |
Artificial intelligence, Commerce | Seed, Early stage venture, Late stage venture | 31% | 2 |
Table 1. Biotech investors in Shanghai, China: venture capital and micro VC funds ranked by biotech companies whose most recent round closed in the last 12 months. Leads is the share of all recorded investments where the fund was lead investor. Source: FundingWatcher. Data as of 16 November 2026.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Investor | Type | Location | Phone | |
|---|---|---|---|---|
| Qiming Venture Partners | Venture capital firm | Shanghai, China | •••@qimingvc.com | (+86) ••• |
| Lilly Asia Ventures | Venture capital firm | Shanghai, China | •••@lillyasiaventures.com | +86 21••• |
| New Alliance Capital | Private equity firm | Shanghai, China | •••@nac-capital.com | 86-21-••• |
| Luminous Ventures (former Lightspeed China Partners) | Venture capital firm | Shanghai, China | •••@luminousvc.com | +86 21••• |
| Chengwei Capital | Venture capital firm | Shanghai, China | •••@chengwei.com | |
| Hengxu Capital | Private equity firm | Jiading, China | •••@hengxucapital.com | 021-22••• |
| Pan-Lin Capital | Venture capital firm | Shanghai, China | •••@panlincap.com | 021-51••• |
| Viva BioInnovator | Venture capital firm | Shanghai, China | •••@vivabiotech.com |
8 rows of the CSV in 5 of its 15 columns, email and phone masked.
- 20 of the 28 biotech investors in Shanghai, China have a published email address, 21 a phone number and 27 a website.
- Qiming Venture Partners has the most recorded investments, 1,106, 555 of them as lead investor.
- 23 of them are investors in at least one company that closed its most recent round in the last 12 months.
- Qiming Venture Partners is an investor in 21 of those companies, more than any other investor on this list.
- The newest round among their portfolio companies is Enjosim's $30.1M Series B on 2 November 2026.
- Software is the most common sector across their 509 portfolio companies (59%).
- Early stage venture is the most common investment stage, recorded for 25 of them (89%).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Biotech investors in Shanghai, China
27 of 28, most investments first| # | Investor | Type | Location | Invests in | Latest portfolio companies | Funded, 12 months | Investments | Lead | Exits | Phone | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Qiming Venture Partners | Venture capital firm | Shanghai, China | Health care, Artificial intelligence | Houmo.AI, Infinigence, AusperBio | 21 | 1,106 | 555 | 104 | •••@qimingvc.com | (+86) ••• | In the CSV |
| 2 | Lilly Asia Ventures | Venture capital firm | Shanghai, China | Health care, Biotech | Precede Biosciences, Akura Medical | 2 | 237 | 68 | 49 | •••@lillyasiaventures.com | +86 21••• | In the CSV |
| 3 | 5Y Capital | Venture capital firm | Xuhui, China | Artificial intelligence, Commerce | Etern, CellCentric, BOTINKIT | 4 | 345 | 108 | 28 | +86 20••• | In the CSV | |
| 4 | BioTrack Capital | Venture capital firm | Shanghai, China | Health care, Biotech | Yuce Biotechnology, Shenluo Medical, Rigen Biotech | 3 | 85 | 28 | 5 | +86-02••• | ||
| 5 | Prox Ventures | Venture capital firm | Shanghai, China | Biotech, Health care | Leadinno Medical Valley | 1 | 71 | 14 | 1 | In the CSV | ||
| 6 | New Alliance Capital | Private equity firm, Venture capital firm | Shanghai, China | Health care, Biotech | Degron Therapeutics | 1 | 96 | 9 | 10 | •••@nac-capital.com | 86-21-••• | In the CSV |
| 7 | Luminous Ventures (former Lightspeed China Partners) | Venture capital firm | Shanghai, China | Hardware, Commerce | Enjosim, Yin Gong Technology, Urtopia | 8 | 182 | 70 | 13 | •••@luminousvc.com | +86 21••• | |
| 8 | Chengwei Capital | Venture capital firm | Shanghai, China | Hardware, Biotech | Huizhi International Tourism, Full-Life Technologies | 2 | 113 | 43 | 11 | •••@chengwei.com | In the CSV | |
| 9 | Linear Capital | Venture capital firm | Shanghai, China | Artificial intelligence, Hardware | SynMetaBio, Dishi Medical, ReaVis | 3 | 83 | 26 | 1 | +61 36••• | In the CSV | |
| 10 | Hengxu Capital | Private equity firm | Jiading, China | Health care, Biotech | Kai Medtech, Runxin Micro Technology, Xingsai Bio | 3 | 82 | 27 | 6 | •••@hengxucapital.com | 021-22••• | |
| 11 | Pan-Lin Capital | Venture capital firm | Shanghai, China | Health care, Biotech | Kunteng Tech, AOSSCI, Levinthal | 3 | 74 | 31 | 6 | •••@panlincap.com | 021-51••• | In the CSV |
| 12 | Viva BioInnovator | Venture capital firm | Shanghai, China | Biotech, Health care | Arthrosi Therapeutics, TechnoDerma Medicines, i2o Therapeutics | 70 | 8 | 5 | •••@vivabiotech.com | In the CSV | ||
| 13 | Boyuan Capital | Venture capital firm | Shanghai, China | Health care, Biotech | Yuce Biotechnology, Rigen Biotech | 2 | 42 | 16 | 5 | In the CSV | ||
| 14 | Med-Fine Capital | Venture capital firm | Shanghai, China | Health care, Biotech | Leadinno Medical Valley, Artivila Therapeutics, Degron Therapeutics | 5 | 77 | 23 | 3 | •••@medfinecapital.com | +86 21••• | In the CSV |
| 15 | Shanghai Biomedical Industrial Equity Investment Fund | Venture capital firm | Huangpu, China | Health care, Biotech | Haimai Medical, AccuPulse, Surgerii Technology | 4 | 60 | 34 | 6 | |||
| 16 | Grand Flight Investment | Private equity firm, Venture capital firm | Shanghai, China | Biotech, Health care | YolTech Therapeutics | 1 | 52 | 19 | 8 | •••@gfinvestment.com | 021-20••• | |
| 17 | Neovision Capital | Venture capital firm | Shanghai, China | Biotech, Health care | Matrixtime Robotics, Xingsai Bio | 2 | 36 | 9 | 5 | •••@neovisioncap.com | +8621 ••• | |
| 18 | Panacea Venture | Venture capital firm | Shanghai, China | Biotech, Health care | Myrtelle | 1 | 21 | 5 | 1 | •••@panaceaventure.com | (86-21••• | In the CSV |
| 19 | DT Capital Partners | Private equity firm, Venture capital firm | Shanghai, China | Fintech, Artificial intelligence | Drug Farm | 1 | 154 | 40 | 19 | •••@dtcap.com | +86(21••• | In the CSV |
| 20 | Fosun International | Venture capital firm | Shanghai, China | Artificial intelligence, Fintech | ROBOT++ | 1 | 122 | 53 | 24 | •••@fosun.com | (86 21••• | In the CSV |
| 21 | Loyal Valley Capital | Private equity firm | Shanghai, China | Health care, Education | Surgerii Technology | 1 | 103 | 48 | 27 | •••@loyalvalleycapital.com | +86 (2••• | In the CSV |
| 22 | Glory Ventures | Venture capital firm | Shanghai, China | Hardware, Artificial intelligence | SINOITS, SpacemiT, Silicon Innovation | 3 | 98 | 28 | 9 | •••@glory-ventures.com | 021-61••• | In the CSV |
| 23 | Dalton Venture | Venture capital firm | Shanghai, China | Health care, Artificial intelligence | Astribot | 1 | 67 | 25 | 1 | •••@daltonventure.cn | 021-62••• | |
| 24 | Marathon Venture Partners | Venture capital firm | Shanghai, China | Fintech, Health care | Natus, Yuanyi Biotech, Doctor AI Yisheng Intelligence | 60 | 29 | 0 | •••@marathonvp.com | +86108••• | In the CSV | |
| 25 | LongRiver Investments | Venture capital firm | Xuhui, China | Health care, Biotech | Rona Therapeutics, Ouro Medicines, Tuge Medical Technology | 22 | 11 | 2 | •••@lr-investments.com | +86 21••• | In the CSV | |
| 26 | Jianxin Capital | Venture capital firm | Shanghai, China | Biotech, Health care | Huadao Biopharma, Hegea Bio | 21 | 1 | 5 | •••@jianxincapital.com | 021-62••• | In the CSV | |
| 27 | Zhongsu Capital | Private equity firm, Venture capital firm | Shanghai, China | Biotech, Health care | Jushu Biotech, Silicon Yi Technology | 11 | 6 | 0 |
Table 2. Biotech investors in Shanghai, China: the first 27 by recorded investments with a website and a location. Email and phone are masked here and complete in the CSV. Source: FundingWatcher. Data as of 16 November 2026. Base: 28.
Most active in the last 12 months
By portfolio companies funded| # | Investor | Location | Funded, 12 months | Portfolio | Latest |
|---|---|---|---|---|---|
| 1 | Qiming Venture Partners | Shanghai, China | 21 | 154 | Houmo.AI, Infinigence, AusperBio |
| 2 | Luminous Ventures (former Lightspeed China Partners) | Shanghai, China | 8 | 48 | Enjosim, Yin Gong Technology, Urtopia |
| 3 | Med-Fine Capital | Shanghai, China | 5 | 8 | Leadinno Medical Valley, Artivila Therapeutics, Degron Therapeutics |
| 4 | 5Y Capital | Xuhui, China | 4 | 57 | Etern, CellCentric, BOTINKIT |
| 5 | Shanghai Biomedical Industrial Equity Investment Fund | Huangpu, China | 4 | 11 | Haimai Medical, AccuPulse, Surgerii Technology |
| 6 | Pan-Lin Capital | Shanghai, China | 3 | 14 | Kunteng Tech, AOSSCI, Levinthal |
| 7 | BioTrack Capital | Shanghai, China | 3 | 9 | Yuce Biotechnology, Shenluo Medical, Rigen Biotech |
| 8 | Hengxu Capital | Jiading, China | 3 | 11 | Kai Medtech, Runxin Micro Technology, Xingsai Bio |
| 9 | Linear Capital | Shanghai, China | 3 | 20 | SynMetaBio, Dishi Medical, ReaVis |
| 10 | Glory Ventures | Shanghai, China | 3 | 23 | SINOITS, SpacemiT, Silicon Innovation |
| 11 | Neovision Capital | Shanghai, China | 2 | 6 | Matrixtime Robotics, Xingsai Bio |
| 12 | Boyuan Capital | Shanghai, China | 2 | 6 | Yuce Biotechnology, Rigen Biotech |
| 13 | Chengwei Capital | Shanghai, China | 2 | 31 | Huizhi International Tourism, Full-Life Technologies |
| 14 | Lilly Asia Ventures | Shanghai, China | 2 | 14 | Precede Biosciences, Akura Medical |
| 15 | Dalton Venture | Shanghai, China | 1 | 9 | Astribot |
Table 3. Biotech investors in Shanghai, China: investors in the most companies whose most recent round falls in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Latest rounds in their portfolios
Newest first| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors on this list | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Enjosim | Enjosim researches, manufactures, and sells self-delivery systems for biomacromolecule pharmaceuticals. | Biotech | Shanghai, China | Series B | $30.1M | 2026-11-02 | $30.1M | Luminous Ventures (former Lightspeed China Partners) | 51 to 100 | 2021 |
| Astribot | Astribot develops intelligent robotic systems that assist people in everyday and professional settings. | Artificial intelligence | Shenzhen, China | Series B | $149.4M | 2026-10-13 | $297.2M | Dalton Venture | 101 to 250 | 2022 |
| Infinigence | Infinigence develops AI infrastructure and computing solutions for training and deploying AI models. | Artificial intelligence | Xuhui, China | Series C | $343.7M | 2026-10-12 | $587.5M | Qiming Venture Partners | 51 to 100 | 2023 |
| Yuce Biotechnology | Yuce Biotechnology focuses on the industrialization of single-molecule immunodiagnostic technologies. | Biotech | Suzhou, China | Series B | $7.4M | 2026-08-31 | $22.4M | BioTrack Capital, Boyuan Capital | 101 to 250 | 2019 |
| AusperBio | AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. | Biotech | Hangzhou, China | Series C | $120.0M | 2026-08-27 | $357.0M | Qiming Venture Partners, Hankang Capital | 51 to 100 | 2019 |
| Leadinno Medical Valley | Leadinno Medical Valley produces medical devices that regulate neurological functions. | Health care | Beijing, China | Series B | $29.7M | 2026-08-17 | $90.3M | Prox Ventures, Med-Fine Capital | 10,001 or more | 2016 |
| Kai Medtech | Kai Medtech markets and sells vascular intervention medical devices. | Health care | Minhang, China | Series D | $73.9M | 2026-07-28 | $105.3M | Hengxu Capital | 51 to 100 | 2019 |
| Drug Farm | Drug Farm develops therapies for infectious, immunological, and inflammatory diseases using genetics and artificial intelligence. | Artificial intelligence | Shanghai, China | Series D | $55.0M | 2026-07-13 | $138.0M | DT Capital Partners | 101 to 250 | 2015 |
| Tianhu Technology | Tianhu Technology uses computational chemistry and artificial intelligence to design new drug molecules. | Artificial intelligence | Minhang, China | Series A | $29.0M | 2026-07-13 | $54.2M | Qiming Venture Partners | 11 to 50 | 2021 |
| SynMetaBio | SynMetaBio develops synthetic biological materials by combining synthetic biology with material design. | Biotech | Shanghai, China | Series A | $14.7M | 2026-07-06 | $16.1M | Linear Capital | 11 to 50 | 2021 |
Table 4. Biotech investors in Shanghai, China: the 10 most recent rounds of companies they back. Source: FundingWatcher. Data as of 16 November 2026.
Portfolio sectors
| Portfolio sectors | Companies | Share |
|---|---|---|
| Software | 302 | 59% |
| Health care | 147 | 29% |
| Biotech | 106 | 21% |
| Hardware | 103 | 20% |
| Artificial intelligence | 101 | 20% |
| Fintech | 47 | 9% |
| Commerce | 39 | 8% |
| Education | 23 | 5% |
| Energy | 12 | 2% |
| Cybersecurity | 10 | 2% |
Table 5. Biotech investors in Shanghai, China: portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.
Investment stages
| Investment stages | Investors | Share |
|---|---|---|
| Early stage investors | 25 | 89% |
| Late stage investors | 21 | 75% |
| Seed investors | 18 | 64% |
| Venture investors | 15 | 54% |
| Private equity investors | 7 | 25% |
| Post IPO investors | 4 | 14% |
Table 6. Biotech investors in Shanghai, China by stage they invest at. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Investors | Share |
|---|---|---|
| Shanghai | 24 | 86% |
| Xuhui | 2 | 7% |
| Jiading | 1 | 4% |
| Huangpu | 1 | 4% |
Table 7. Biotech investors in Shanghai, China by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Founded
| Founded | Investors | Share |
|---|---|---|
| 2020s | 3 | 11% |
| 2010s | 16 | 59% |
| 2000s | 6 | 22% |
| 1990s | 2 | 7% |
Table 8. Biotech investors in Shanghai, China by founding decade. Source: FundingWatcher. Data as of 16 November 2026.
Method
- An investor is on this list when it is recorded as an investor in 2 or more funded biotech companies and its headquarters is in Shanghai, China. On 16 November 2026 that is 28 investors.
- 20 rows carry an email address and 21 a phone number from the investor file. Investments, lead investments and exits are the counts the source records.
- The table prints the first 27 rows by recorded investments that carry a website and a location, with email and phone masked. The CSV carries all 28 rows: 1 have no website and 0 no location.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech investors in Shanghai, China are on the list?
- 28, in the file dated 16 November 2026. 23 of them invested in a company whose most recent round falls in the last 12 months.
- How many have an email address?
- 20 of the 28 carry an email address in the download and 21 a phone number.
- What does the CSV contain?
- One row per investor, 15 columns: name, types, stages, city, region, country, founded, website, linkedin, investments, funded_last_12m, exits, lead_investments, email, phone.
- How much does the list cost?
- $29 one-time for all 28 rows, no account. Every investor and every startup, two files, cost $99. With partner contacts, up to 2 per firm compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV with 28 rows, 20 firm email addresses and 21 phone numbers, on the page after payment and by mail. The emails are the address a firm publishes: 14 of the 20 are inboxes such as info@ or contact@. No partner names.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.